Company: ABUS
Filing Date: 2025-03-03
Form Type: 8-K
Source: 0001171843-25-001188
Chunk: 2

Company: Arbutus Biopharma Corp
Filing Date: 2025-03-03
Form: 8-K
Item: Item 8.01
Chunk 2
---
Item 8.01. Other Events.

On March 3, 2025, the Company provided notice to Moderna that the Company was terminating the Non-Exclusive License Agreement, dated as of October 12, 2016 (the “ Sublicense Agreement”), by and between Acuitas Therapeutics Inc. and ModernaTX, Inc., an affiliate of Moderna, Inc. (“ ModernaTX”), in its capacity as an express third-party beneficiary, for material breach of the Sublicense Agreement. Specifically, the Company claims ModernaTX owes certain milestone and royalty payments, and ModernaTX’s failure to remit such milestone payments and royalty payments constitutes a material breach of the Sublicense Agreement. Under the Sublicense Agreement, ModernaTX has sixty (60) days to cure its material breach, and, if ModernaTX does not cure this breach within the specified time-period, including by paying any milestone or ongoing royalty payments owed, the Company’s termination of the Sublicense Agreement shall be effective as of the notification date.

On March 3, 2025, the Company and Genevant filed five international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle technology against Moderna, Inc., ModernaTX, and certain affiliates.

On March 3, 2025, the Company issued a press release announcing the foregoing lawsuit filings. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

  Exhibit Number      Description                                                                                              
            10.1      Agreement, dated March 2, 2025, by and between Arbutus Biopharma Corporation and Genevant Sciences GmbH  
            99.1      Press Release dated March 3, 2025                                                                        
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
             104      Cover Page Interactive Data File (embedded within the Inline XBRL document)